©The Author(s) 2020.
World J Gastrointest Oncol. Jun 15, 2020; 12(6): 663-676
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663
Table 1 Baseline characteristics
| Parameter | Number of participants (n = 66) |
| Mean age (yr) | 53.3 ± 13.6 |
| Sex | |
| Male | 55 |
| Female | 11 |
| Maximum tumor diameter (cm) | |
| ≤ 5 | 27 |
| 5-10 | 26 |
| > 10 | 13 |
| Child-Pugh score | |
| A | 57 |
| B7 | 9 |
| BCLC stage | |
| B | 29 |
| C | 37 |
| ECOG PS | |
| 0 | 46 |
| 1 | 20 |
| Vascular invasion | |
| Present | 25 |
| Absent | 41 |
| Portal vein invasion | |
| Present | 23 |
| Absent | 43 |
| Extrahepatic metastasis | |
| Present | 16 |
| Absent | 50 |
| HBV | |
| Positive | 54 |
| Negative | 12 |
| HBV DNA (copies/mL) | |
| > 2 × 103 | 30 |
| ≤ 2 × 103 | 36 |
| Cirrhosis | |
| Present | 50 |
| Absent | 16 |
| AFP (ng/mL) | |
| ≤ 100 | 26 |
| > 100 | 40 |
- Citation: Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676
- URL: https://www.wjgnet.com/1948-5204/full/v12/i6/663.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.663